GRAIL Inc (GRAL) Stock Forecast & Price Target

GRAIL is attractive because Galleri has a differentiated clinical foundation, with over 300K tests processed in studies and trials, specificity at 99.6%, and Cancer Signal Origin accuracy above 90%, which supports its role as a leading multi-cancer detection platform. The company’s large, underpenetrated market opportunity is reinforced by PATHFINDER 2 and NHS-Galleri, where sensitivity improved to 39% from 29% and Stage IV cancers fell 14%, suggesting real clinical utility and long-term adoption potential. Positive regulatory momentum, including the prospect of FDA approval in late 2026 or 1H27 and a formal Medicare reimbursement pathway under the February 2026 coverage act, could unlock materially stronger revenue growth and de-risk commercialization.

GRAIL is challenged by a lengthy, costly clinical and regulatory path, with delays or unexpected data risking FDA approval, broader reimbursement, and product launch timing, while Galleri still lacks Medicare coverage despite private payer wins. It has incurred significant net losses since inception and is expected to keep burning cash as commercialization spending remains heavy; the company also faces a roughly 7% Illumina royalty resuming in 2027, which could pressure margins if volume ramps lag expectations. Demand appears structurally constrained by a $949 cash-pay price, weak conversion even in affluent channels, and limited coverage visibility before the 2029 Medicare phase-in, leaving revenue upside below Street assumptions and OpEx likely above revenue for the next five years.